Genmab has been boosted by new data for its antibody-drug conjugate, rinatabart sesutecan (Rina-S), but is aiming to move fast to keep ahead of competitor Lilly.
The latest Phase I/II trial results from the RAINFOL-1 study showed that Rina-S treatment led to a confirmed objective response...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?